Hamilton Wealth LLC Has $12.30 Million Stock Position in Moderna, Inc. $MRNA

Hamilton Wealth LLC grew its holdings in Moderna, Inc. (NASDAQ:MRNA) by 130.5% in the first quarter, HoldingsChannel reports. The fund owned 242,184 shares of the company’s stock after buying an additional 137,118 shares during the period. Hamilton Wealth LLC’s holdings in Moderna were worth $12,303,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. MUFG Securities EMEA plc bought a new position in Moderna during the second quarter worth about $28,000. Flagship Harbor Advisors LLC bought a new stake in Moderna in the 4th quarter valued at about $31,000. Canton Hathaway LLC acquired a new position in shares of Moderna during the 1st quarter worth approximately $31,000. Cromwell Holdings LLC grew its position in shares of Moderna by 39.7% during the 4th quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock worth $35,000 after purchasing an additional 341 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its holdings in shares of Moderna by 148.3% during the second quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock worth $37,000 after purchasing an additional 801 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Stock Performance

Shares of Moderna stock opened at $54.49 on Thursday. The company has a 50 day moving average of $59.00 and a 200-day moving average of $52.33. Moderna, Inc. has a 1-year low of $22.28 and a 1-year high of $85.60. The company has a current ratio of 2.41, a quick ratio of 2.35 and a debt-to-equity ratio of 0.08. The company has a market cap of $21.62 billion, a PE ratio of -6.69 and a beta of 0.94.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Friday, May 1st. The company reported ($3.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). The firm had revenue of $389.00 million during the quarter, compared to the consensus estimate of $236.37 million. Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. The business’s revenue was up 260.2% compared to the same quarter last year. During the same period last year, the business earned ($2.52) earnings per share. As a group, equities research analysts forecast that Moderna, Inc. will post -6.41 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on MRNA shares. Morgan Stanley lifted their price target on shares of Moderna from $33.00 to $39.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 8th. Bank of America raised their price objective on Moderna from $34.00 to $38.00 and gave the stock an “underperform” rating in a research note on Tuesday, July 7th. The Goldman Sachs Group lifted their price objective on Moderna from $49.00 to $67.00 and gave the company a “neutral” rating in a report on Tuesday, July 21st. UBS Group reiterated a “neutral” rating on shares of Moderna in a research report on Tuesday, May 26th. Finally, Jefferies Financial Group reissued a “hold” rating on shares of Moderna in a report on Thursday, June 18th. Two research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and five have issued a Sell rating to the stock. According to MarketBeat, Moderna presently has a consensus rating of “Reduce” and a consensus price target of $40.00.

Insiders Place Their Bets

In other news, insider Shannon Thyme Klinger sold 3,471 shares of the business’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total transaction of $173,550.00. Following the completion of the transaction, the insider owned 67,468 shares of the company’s stock, valued at approximately $3,373,400. The trade was a 4.89% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Noubar Afeyan sold 9,263 shares of the business’s stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $46.84, for a total value of $433,878.92. Following the transaction, the director directly owned 3,924 shares of the company’s stock, valued at $183,800.16. This trade represents a 70.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 125,088 shares of company stock valued at $6,193,713 over the last ninety days. Company insiders own 10.80% of the company’s stock.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.